Immune checkpoint inhibitors: possibility of adverse rheumatoid events

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The incidence of rheumatic immune-related adverse events (IRAEs) resulting from treatment with immune checkpoint inhibitors (ICI) remains unclear, but significant.

Why this matters

  • Physicians should be aware of the potential for rheumatoid side effects of ICI treatment.

Study design

  • Prevalence, clinical characteristics, and treatment data were extracted and summarized from studies that reported musculoskeletal and rheumatic IRAEs with ICI treatment.
  • Funding: Not indicated.

Key results

  • 52 studies with original data on ICI treatment and information about musculoskeletal or rheumatic IRAEs were selected, including 33 clinical trials, 3 observational studies, and 16 series or case reports.
  • Among clinical trials, arthralgia was reported in 24 trials and incidence ranged from 1% to 43%, myalgia was reported in 12 and ranged from 2% to 21%, arthritis reported in 5 and ranged from 1% to 7%, and a case of giant cell vasculitis reported in 1 trial and unspecified vasculitis in another trial.
  • Among observational and case studies, there were reports of vasculitis, myositis, inflammatory arthritis, and lupus nephritis.

Limitations

  • Inconsistent classification and limited data on IRAEs.